Sugi Predict

Sugi Predict / Compounds / SCHEMBL75490

SCHEMBL75490

SCHEMBL75490

NC1C2CC3CC1CC(O)(C3)C2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PKM P14618 1/20 0.37
▸ HSD11B1 P28845 8/20 0.36
▸ HSD11B2 P80365 2/20 0.36
▸ EPHX2 P34913 4/20 0.33
▸ LMNA P02545 2/20 0.32
▸ SLC22A2 O15244 1/20 0.32
▸ SLC22A1 O15245 1/20 0.32
▸ GRIN2D O15399 1/20 0.32
▸ GRIN3B O60391 1/20 0.32
▸ TSHR P16473 1/20 0.32
▸ NFKB1 P19838 1/20 0.32
▸ STAT6 P42226 1/20 0.32
▸ GRIN1 Q05586 1/20 0.32
▸ GRIN2A Q12879 1/20 0.32
▸ GRIN2B Q13224 1/20 0.32
▸ GRIN2C Q14957 1/20 0.32
▸ GRIN3A Q8TCU5 1/20 0.32
▸ SLC47A1 Q96FL8 1/20 0.32
▸ SIGMAR1 Q99720 1/20 0.32
▸ JAK2 O60674 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4405412 1.00 PKM (0.37) PKMHSD11B1HSD11B2EPHX2LMNA
SCHEMBL12861211 1.00 PKM (0.37) PKMHSD11B1HSD11B2EPHX2LMNA
SCHEMBL256757 1.00 PKM (0.37) PKMHSD11B1HSD11B2EPHX2LMNA
SCHEMBL10138542 1.00 PKM (0.37) PKMHSD11B1HSD11B2EPHX2LMNA
SCHEMBL1154281 1.00 PKM (0.37) PKMHSD11B1HSD11B2EPHX2LMNA
SCHEMBL3510056 1.00 PKM (0.37) PKMHSD11B1HSD11B2EPHX2LMNA
SCHEMBL2812490 1.00 PKM (0.37) PKMHSD11B1HSD11B2EPHX2LMNA
SCHEMBL974709 1.00 PKM (0.37) PKMHSD11B1HSD11B2EPHX2LMNA
SCHEMBL13171860 1.00 PKM (0.37) PKMHSD11B1HSD11B2EPHX2LMNA
SCHEMBL974708 1.00 PKM (0.37) PKMHSD11B1HSD11B2EPHX2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 546 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116656296-B High-temperature-resistant packaging adhesive for electronic components and manufacturing process thereof 烟台固邦新材料有限公司 2025-04-18 — — CN claimed
CN-116789600-A Preparation method and application of novel tetrahydroindazole antitumor compound 深圳市人民医院 2023-09-22 — — CN claimed
CN-116656296-A High-temperature-resistant packaging adhesive for electronic components and manufacturing process thereof 烟台固邦新材料有限公司 2023-08-29 — — CN claimed
CN-112341406-B Synthesis method of trans-4- [4- (3-methoxy-4-nitrophenyl) -1-piperazinyl ] adamantane-1-ol 韶远科技（上海)有限公司 2023-02-10 — — CN claimed
WO-2022105046-A1 SYNTHESIS METHOD OF TRANS-4-[4-(3-METHOXY-4-NITROPHENYL)-1-PIPERAZINYL]ADAMANTANE-1-OL 韶远科技（上海)有限公司 2022-05-27 — — WO claimed
CN-112341406-A Synthesis method of trans-4- [4- (3-methoxy-4-nitrophenyl) -1-piperazinyl ] adamantane-1-ol 韶远科技（上海)有限公司 2021-02-09 — — CN claimed
CN-105693528-A Trans-4-aminoadamantan-1-ol hydrochloride synthesis technology 青岛首冠企业管理咨询有限公司 2016-06-22 — — CN claimed
CN-105646243-A Trans-4-amino-1-adamantanol hydrochloride synthesis process 吕艳 2016-06-08 — — CN claimed
EP-1999114-B1 PYRAZOLES AS 11-BETA-HSD-1 HOFFMANN LA ROCHE (CH) 2015-07-22 — — EP claimed
EP-2459549-B1 TETRAHYDROQUINOXALINE UREA DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2014-11-19 — — EP claimed
EP-1935420-A1 2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors Merck Sante (FR) 2008-06-25 — — EP claimed
WO-2007144394-A2 PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES HIGH POINT PHARMACEUTICALS, LLC. (US) 2007-12-21 — — WO claimed
WO-2007107470-A2 PYRAZOLES AS 11-BETA-HSD-1 F. HOFFMANN-LA ROCHE AG (CH) 2007-09-27 — — WO claimed
US-20070225280-A1 Adamantyl-pyrazole carboxamides as inhibitors of 11B-hydroxysteroid dehydrogenase ANDERSON KEVIN WILLIAM 2007-09-27 — — US claimed
WO-2007082808-A2 THIAZOLES AS 11 BETA-HSD1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2007-07-26 — — WO claimed
US-20070167622-A1 [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome GILLESPIE PAUL 2007-07-19 — — US claimed
WO-2007051811-A2 PHARMACEUTICAL USE OF SUBSTITUTED AMIDES TRANSTECH PHARMA (US) 2007-05-10 — — WO claimed
US-20060079506-A1 Adamantyl acetamides as 11-beta hydroxysteroid dehydrogenase inhibitors JANSSEN PHARMACEUTICAL N.V. (BE) 2006-04-13 — — US claimed
EP-1581476-A2 ADAMANTYL ACETAMIDES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2005-10-05 — — EP claimed
WO-2004056745-A2 ADAMANTYL ACETAMIDES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2004-07-08 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225280-A1 Adamantyl-pyrazole carboxamides as inhibitors of 11B-hydroxysteroid dehydrogenase HSD3B2, HSD3B1, HSD17B2 PKM 1302/4885HSD11B1 6/4885HSD11B2 5/4885
US-20060079506-A1 Adamantyl acetamides as 11-beta hydroxysteroid dehydrogenase inhibitors DHCR7, HSD3B2, HSD3B1 PKM 4843/4885HSD11B1 5/4885HSD11B2 8/4885
US-20070167622-A1 [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome GOT2, PC, CYP11B2 PKM 205/4885HSD11B1 210/4885HSD11B2 149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.